U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination
    • Showing Current items.

    OSM oncostatin M [ Homo sapiens (human) ]

    Gene ID: 5008, updated on 3-Apr-2024

    GeneRIFs: Gene References Into Functions

    GeneRIFPubMed TitleDate
    Exercise-induced crosstalk between immune cells and adipocytes in humans: Role of oncostatin-M.

    Exercise-induced crosstalk between immune cells and adipocytes in humans: Role of oncostatin-M.
    Dollet L, Lundell LS, Chibalin AV, Pendergrast LA, Pillon NJ, Lansbury EL, Elmastas M, Frendo-Cumbo S, Jalkanen J, de Castro Barbosa T, Cervone DT, Caidahl K, Dmytriyeva O, Deshmukh AS, Barrès R, Rydén M, Wallberg-Henriksson H, Zierath JR, Krook A., Free PMC Article

    01/30/2024
    Oncostatin M for characterizing the inflammatory burden and outcome of V-V ECMO in ARDS patients.

    Oncostatin M for characterizing the inflammatory burden and outcome of V-V ECMO in ARDS patients.
    Setiadi H, El-Banayosy AM, Long JW, Maybauer MO, Mihu MR, El Banayosy A.

    12/20/2023
    Oncostatin M suppresses IL31RA expression in dorsal root ganglia and interleukin-31-induced itching.

    Oncostatin M suppresses IL31RA expression in dorsal root ganglia and interleukin-31-induced itching.
    Suehiro M, Numata T, Saito R, Yanagida N, Ishikawa C, Uchida K, Kawaguchi T, Yanase Y, Ishiuji Y, McGrath J, Tanaka A., Free PMC Article

    12/5/2023
    Role of oncostatin-M in ECM remodeling and plaque vulnerability.

    Role of oncostatin-M in ECM remodeling and plaque vulnerability.
    Patel P, Rai V, Agrawal DK., Free PMC Article

    11/16/2023
    Pancreatic Stromal Cell-derived Oncostatin M Confers Drug Resistance to a Multi-tyrosine Kinase Inhibitor in Pancreatic Cancer Cells.

    Pancreatic Stromal Cell-derived Oncostatin M Confers Drug Resistance to a Multi-tyrosine Kinase Inhibitor in Pancreatic Cancer Cells.
    Tatsuda D, Yoshida J, Ohishi T, Kawada M.

    06/2/2023
    Evidence that oncostatin M synergizes with IL-4 signaling to induce TSLP expression in chronic rhinosinusitis with nasal polyps.

    Evidence that oncostatin M synergizes with IL-4 signaling to induce TSLP expression in chronic rhinosinusitis with nasal polyps.
    Wang BF, Cao PP, Norton JE, Poposki JA, Klingler AI, Suh LA, Carter R, Huang JH, Bai J, Stevens WW, Tan BK, Peters AT, Grammer LC, Conley DB, Welch KC, Liu Z, Kern RC, Kato A, Schleimer RP., Free PMC Article

    05/11/2023
    Oncostatin M Contributes to Airway Epithelial Cell Dysfunction in Chronic Rhinosinusitis with Nasal Polyps.

    Oncostatin M Contributes to Airway Epithelial Cell Dysfunction in Chronic Rhinosinusitis with Nasal Polyps.
    Carsuzaa F, Bequignon E, Bartier S, Coste A, Dufour X, Bainaud M, Lecron JC, Louis B, Tringali S, Favot L, Fieux M., Free PMC Article

    04/15/2023
    Exogenous Oncostatin M induces Cardiac Dysfunction, Musculoskeletal Atrophy, and Fibrosis.

    Exogenous Oncostatin M induces Cardiac Dysfunction, Musculoskeletal Atrophy, and Fibrosis.
    Jengelley DHA, Wang M, Narasimhan A, Rupert JE, Young AR, Zhong X, Horan DJ, Robling AG, Koniaris LG, Zimmers TA., Free PMC Article

    10/1/2022
    Oncostatin M Improves Cutaneous Wound Re-Epithelialization and Is Deficient under Diabetic Conditions.

    Oncostatin M Improves Cutaneous Wound Re-Epithelialization and Is Deficient under Diabetic Conditions.
    Das A, Madeshiya AK, Biswas N, Ghosh N, Gorain M, Rawat A, Mahajan SP, Khanna S, Sen CK, Roy S., Free PMC Article

    05/14/2022
    The Role of Oncostatin M and Its Receptor Complexes in Cardiomyocyte Protection, Regeneration, and Failure.

    The Role of Oncostatin M and Its Receptor Complexes in Cardiomyocyte Protection, Regeneration, and Failure.
    Kubin T, Gajawada P, Bramlage P, Hein S, Berge B, Cetinkaya A, Burger H, Schönburg M, Schaper W, Choi YH, Richter M., Free PMC Article

    04/16/2022
    Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis.

    Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis.
    Di Maira G, Foglia B, Napione L, Turato C, Maggiora M, Sutti S, Novo E, Alvaro M, Autelli R, Colombatto S, Bussolino F, Carucci P, Gaia S, Rosso C, Biasiolo A, Pontisso P, Bugianesi E, Albano E, Marra F, Parola M, Cannito S., Free PMC Article

    04/16/2022
    Oncostatin M expression induced by bacterial triggers drives airway inflammatory and mucus secretion in severe asthma.

    Oncostatin M expression induced by bacterial triggers drives airway inflammatory and mucus secretion in severe asthma.
    Headland SE, Dengler HS, Xu D, Teng G, Everett C, Ratsimandresy RA, Yan D, Kang J, Ganeshan K, Nazarova EV, Gierke S, Wedeles CJ, Guidi R, DePianto DJ, Morshead KB, Huynh A, Mills J, Flanagan S, Hambro S, Nunez V, Klementowicz JE, Shi Y, Wang J, Bevers J 3rd, Ramirez-Carrozzi V, Pappu R, Abbas A, Vander Heiden J, Choy DF, Yadav R, Modrusan Z, Panettieri RA Jr, Koziol-White C, Jester WF Jr, Jenkins BJ, Cao Y, Clarke C, Austin C, Lafkas D, Xu M, Wolters PJ, Arron JR, West NR, Wilson MS.

    04/16/2022
    Oncostatin M suppresses browning of white adipocytes via gp130-STAT3 signaling.

    Oncostatin M suppresses browning of white adipocytes via gp130-STAT3 signaling.
    van Krieken PP, Odermatt TS, Borsigova M, Blüher M, Wueest S, Konrad D., Free PMC Article

    03/26/2022
    Oncostatin M sensitizes keratinocytes to UVB-induced inflammation via GSDME-mediated pyroptosis.

    Oncostatin M sensitizes keratinocytes to UVB-induced inflammation via GSDME-mediated pyroptosis.
    Liu J, Zhong Y, Liu H, Yang H, Lu P, Shi Y, Wang X, Zheng W, Yu X, Xu Y, Yang B.

    02/26/2022
    Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasis.

    Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasis.
    Lee BY, Hogg EKJ, Below CR, Kononov A, Blanco-Gomez A, Heider F, Xu J, Hutton C, Zhang X, Scheidt T, Beattie K, Lamarca A, McNamara M, Valle JW, Jørgensen C., Free PMC Article

    01/15/2022
    Endothelial Reprogramming Stimulated by Oncostatin M Promotes Inflammation and Tumorigenesis in VHL-Deficient Kidney Tissue.

    Endothelial Reprogramming Stimulated by Oncostatin M Promotes Inflammation and Tumorigenesis in VHL-Deficient Kidney Tissue.
    Nguyen-Tran HH, Nguyen TN, Chen CY, Hsu T., Free PMC Article

    01/8/2022
    Oncostatin M promotes hepatic progenitor cell activation and hepatocarcinogenesis via macrophage-derived tumor necrosis factor-alpha.

    Oncostatin M promotes hepatic progenitor cell activation and hepatocarcinogenesis via macrophage-derived tumor necrosis factor-α.
    Yang X, Shao C, Duan L, Hou X, Huang Y, Gao L, Zong C, Liu W, Jiang J, Ye F, Shi J, Zhao Q, Wu D, Wei L.

    01/8/2022
    Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment.

    Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment.
    Dinca SC, Greiner D, Weidenfeld K, Bond L, Barkan D, Jorcyk CL., Free PMC Article

    01/1/2022
    Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease.

    Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease.
    Verstockt S, Verstockt B, Machiels K, Vancamelbeke M, Ferrante M, Cleynen I, De Hertogh G, Vermeire S., Free PMC Article

    12/25/2021
    Oncostatin-M Does Not Predict Treatment Response in Inflammatory Bowel Disease in a Pediatric Cohort.

    Oncostatin-M Does Not Predict Treatment Response in Inflammatory Bowel Disease in a Pediatric Cohort.
    Ezirike Ladipo J, He Z, Chikwava K, Robbins K, Beri J, Molle-Rios Z.

    10/30/2021
    Oncostatin M upregulates Livin to promote keratinocyte proliferation and survival via ERK and STAT3 signalling pathways.

    Oncostatin M upregulates Livin to promote keratinocyte proliferation and survival via ERK and STAT3 signalling pathways.
    Wang H, Lei L, Hu J, Li Y.

    10/2/2021
    TCF-3-mediated transcription of lncRNA HNF1A-AS1 targeting oncostatin M expression inhibits epithelial-mesenchymal transition via TGFbeta signaling in gastroenteropancreatic neuroendocrine neoplasms.

    TCF-3-mediated transcription of lncRNA HNF1A-AS1 targeting oncostatin M expression inhibits epithelial-mesenchymal transition via TGFβ signaling in gastroenteropancreatic neuroendocrine neoplasms.
    Xue J, Bai J, Long Q, Wei Y, Pan J, Li X, Tang Q., Free PMC Article

    07/24/2021
    Association of serum regenerating islet-derived protein 3-beta and oncostatin-M levels with the risk of acute coronary syndrome in patients with type 2 diabetes mellitus - A pilot study.

    Association of serum regenerating islet-derived protein 3-beta and oncostatin-M levels with the risk of acute coronary syndrome in patients with type 2 diabetes mellitus - A pilot study.
    K M, Adole PS, Vinod KV, Balamurugan N.

    07/10/2021
    Serial Lipocalin 2 and Oncostatin M levels reflect inflammation status and treatment response in axial spondyloarthritis.

    Serial Lipocalin 2 and Oncostatin M levels reflect inflammation status and treatment response in axial spondyloarthritis.
    Tsui FWL, Lin A, Sari I, Zhang Z, Tsui HW, Inman RD., Free PMC Article

    07/10/2021
    Myocardial Accumulations of Reg3A, Reg3gamma and Oncostatin M Are Associated with the Formation of Granulomata in Patients with Cardiac Sarcoidosis.

    Myocardial Accumulations of Reg3A, Reg3γ and Oncostatin M Are Associated with the Formation of Granulomata in Patients with Cardiac Sarcoidosis.
    Gajawada P, Cetinkaya A, von Gerlach S, Kubin N, Burger H, Näbauer M, Grinninger C, Rolf A, Schönburg M, Choi YH, Kubin T, Richter M., Free PMC Article

    05/15/2021
    firstprevious page of 7 nextlast